Journal article
Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia
Clinical lymphoma, myeloma and leukemia, Vol.20(3), pp.e131-e136
03/2020
DOI: 10.1016/j.clml.2019.11.001
PMCID: PMC9302407
PMID: 32029396
Abstract
The role of obesity in prognosis of acute myeloid leukemia (AML) is debatable. Our retrospective study aimed to determine the effect of obesity on overall survival (OS) in AML.
AML patients diagnosed at University of Nebraska Medical Center were divided into 3 groups according to body mass index (BMI): normal (18.5-25 kg/m2) or underweight (< 18.5 kg/m2); overweight (25-30 kg/m2); and obese (≥ 30 kg/m2). Chi-square test, Kruskal-Wallis test, and ANOVA were used to examine the association of BMI with baseline characteristics. Mann-Whitney test was used for pairwise comparisons of hematopoietic cell transplantation (HCT) comorbidity index. Bonferroni correction was used to adjust P values. OS, defined as time from diagnosis to death from any cause, was determined by the Kaplan-Meier method; comparisons of survival curves were done using log-rank test. Cox regression analysis was performed to detect the effect of BMI on OS.
Of 314 patients, 38% were obese, 68% received intensive chemotherapy, and 30% underwent HCT. Patient characteristics for all BMI groups were similar except greater HCT comorbidity index in obese patients. Actual body weight was used to calculate the chemotherapy dose in 92% of obese patients. The rates of receipt of HCT in normal, overweight, and obese groups were 33%, 32%, and 25%, respectively (P = .6). One-year OS values for normal/underweight, overweight, and obese groups was 42%, 45%, and 39%, respectively (P = .31). On multivariate analysis, obesity was associated with worse OS compared to normal-weight (hazard ratio = 0.6; 95% confidence interval, 0.4-0.9; P = .03) but not overweight patients.
Obesity confers worse prognosis in AML. Differences in OS were not the result of differences in chemotherapy dose or receipt of HCT.
We aimed to determine the effect of obesity on overall survival (OS) in acute myeloid leukemia. A total of 314 patients were included in the study; 38% were obese. Actual body weight was used to calculate the chemotherapy dose in 92% of obese patients. Multivariate analysis revealed that obesity, as compared to normal weight, conferred worse OS. OS was similar in obese and overweight patients.
Details
- Title: Subtitle
- Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia
- Creators
- Prajwal Dhakal - University of Nebraska Medical CenterElizabeth Lyden - University of Nebraska Medical CenterAndrea Lee - University of Nebraska Medical CenterJoel Michalski - University of Nebraska Medical CenterZaid S. Al-Kadhimi - University of Nebraska Medical CenterLori J. Maness - University of Nebraska Medical CenterKrishna Gundabolu - University of Nebraska Medical CenterVijaya Raj Bhatt - University of Nebraska Medical Center
- Resource Type
- Journal article
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.20(3), pp.e131-e136
- DOI
- 10.1016/j.clml.2019.11.001
- PMID
- 32029396
- PMCID
- PMC9302407
- NLM abbreviation
- Clin Lymphoma Myeloma Leuk
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Publisher
- Elsevier Inc
- Grant note
- DOI: 10.13039/100004319, name: Pfizer; DOI: 10.13039/100000002, name: National Institutes of Health; DOI: 10.13039/100004336, name: Novartis; DOI: 10.13039/100000054, name: National Cancer Institute, award: P30 CA036727; DOI: 10.13039/100006483, name: AbbVie; DOI: 10.13039/100008322, name: CSL Behring; DOI: 10.13039/100010891, name: Portola Pharmaceuticals; DOI: 10.13039/100000057, name: National Institute of General Medical Sciences, award: 1 U54 GM115458; DOI: 10.13039/501100005612, name: Shionogi
- Language
- English
- Date published
- 03/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359702902771
Metrics
11 Record Views